Obesity and metabolic syndrome treatment with tanshinone...

Details Obesity and metabolic syndrome treatment with tanshinone... Obesity and metabolic syndrome treatment with tanshinone...

2009-09-08

2011-10-04

Hoffman, Susan (Department: 1655)

Drug, bio-affecting and body treating compositions

Plant material or plant extract of undetermined constitution...

Containing or obtained from labiatae

Reexamination Certificate

active

08029832

ABSTRACT:
The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.

REFERENCES:
patent: 2003/0114431 (2003-06-01), Girouard
patent: 1020000027306 (2000-05-01), None
patent: 1020010019147 (2001-03-01), None
patent: 1020040084482 (2004-10-01), None
Stimulation of AMP-Activated Protein Kinase (AMPK) Is Associated with Enhancement of Glut 1-Mediated Glucose Transport; Author: Abbud, et al.;Arch. Biochem. Biophys.;vol. 380,pp. 347-352,2000.
Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase; Author: Zheng, et al.; J. Appl. Physiol.; vol. 91, pp. 1073-1083, 2001.
Coordinate Regulation of Malonyl-CoA Decarboxylase, sn-Glycerol-3-phosphate Acyltransferase, and Acetyl0CoA Carboxylase by AMP-actvated Protein Kinase in Rat Tissues in Response to Exercise; Author: Park, et al.; J. Biol. Chem.; vol. 227,pp. 32571-32577, 2002.
Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle; Author: Park, et al.;J. Appl. Physiol; vol. 92,pp. 2475-2482,2002.
Mechanism for Fatty Acid “Sparing” Effect on Glucose-induced Transcription; Author: Kawagachi, et al.; J. Biol. Chem.; vol. 277, pp. 3829-3835,2002.
Inhibition of Inducible Nitric-oxide Synthase by Activators of AMP-activated Protein Kinase; Author: Pilon, et al.; J. Biol. Chem.; vol. 279,pp. 20767-20774, 2004.
AMP Kinase and Malonyl-COA: Targets for Therapy of the Metaolic Syndrome; Author: Ruderman, et al.; Nature drug discovery; vol. 3,pp. 340-351, Apr. 2004.
PPARy coactivator-1a expression during thyroid hormone-and contractile activity-induced mitochondrial adaptations; Author: Irrcher, et al.;Am. J. Physiol. Cell Physiol.;vol. 284, c1669-c1677, 2003.
AMP-activated protein kinase phosphorylation of endothelial NO synthase; Author: Chen, et al.; FEBS Letters 443,pp. 285-289, 1999.
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1, Author: Patti, et al.;PNAS ;vol. 100, No. 14; pp. 8466-8471, 2003.
Inhibitory Activity of Diacylglycerol Acyltransferase by Tanshinones from the Root Salvia miltiorrhiza; Author: Ko, et al; Arch. Pharm. Res.; vol. 25,pp. 446-448, 2002.
Dihydrosotanshinone I Protects Against Menadione-Induced Toxicity in a Primary Culture of Rat Hepatocytes; Author: Ip, et al.; Planta Med.; 68,pp. 1077-1081, 2002.
Aldose Reductase Inhibitory Constituents of the Root of Salvia miltiorhiza BUNGE; Author: Tezuka, et al.; Chem. Pharm. Bull.; vol. 45, No. 8; pp. 1306-1311,1997.
Possible Aktive Components of Tan-Shen (Salvia miltiorrhiza) for Protection of the Myocardium Against Ischemia-Induced Derangements; Author: Yagi, et al.; Planta Med.; vol. 55; pp. 51-54, 1989.
Role of UCP2 and UCP3 in Nutrition and Obesity;Author: Nagy, et al.; Nutrition; vol. 20, pp. 139-144,2004.
Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia; Author: Marsin, et al.; Curr. Biol.; vol. 10,pp. 1247-1255, 2000.
5-Aminoimidazole-4-Carboxamide Riboside Mimics the Effects of Insulin on the Expression of the 2 Key Gluconeogenic Genes PEPCK and Glucose-6-Phosphatase; Author: Lochead, et al.; Diabetes; vol. 49,pp. 896-903,2000.
Mitochondrial fission in apoptosis, neurodegeneration and aging; Author: Bossy-Wetzel, et al.;Curr. Opin. Cell Biol.; vol. 15, pp. 706-716, 2003.
Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance; Author: Peterson, et al.; Science; vol. 300, pp. 1140-1142, 2003.
Decreased mitochondrial DNA content in peripheral blood precedes the developement of non-insulin-dependent diabetes mellitus; Author: Lee, et al.; Diabetes Res. Clin. Pract.; vol. 42,pp. 161-167, 1998.
Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1; Author: Wu, et al.; Cell; vol. 98, pp. 115-124,1999.
Effects of Tanshinone VI on the Hypertrophy of Cardiac Myocytes and Fibrosis of Cardiac Fibroblasts fo Neonatal Rats; Author: Maki, et al.; Planta Med.; vol. 68, pp. 1103-1107,2002.
Tanshinones inhibit mast cell degranulation by interfering with IgE receptor-mediated tyrosine phosphorylation of PLCgamma2 and MAPK; Author: Choi, et al.; Planta Med.; vol. 70,pp. 178-180, 2004.
Novel Diterpenoid acetylcholinesterase Inhibitors from Salvia miltiorhiza; Author: Ren, et al.; Planta Med.;vol. 70, pp. 201-204, 2004.
Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells; Author: Takahashi, et al.; Biochemical Pharmacology; vol. 64, pp. 745-750, 2002.
Antibacterial Activities of Cryptotanshinonee and Dihydrotanshinone I from a Medicinal Herb, Salvia miltiorrhiza Bunge; Author: Lee, et al.; Biosci. Biotechnol. Biochem.; vol. 63(12), pp. 2236-2239,1999.
Inhibition of interleukin-12 and interferon-y production in imnune cells by tanshinones from Salvia miltiorrhiza; Author: Kang, et al.; Immunopharmacology; vol. 49, pp. 355-361,2000.
Sodium tanshinone IIA sulfonate mediates electron transfer reaction in rat heart mitochondria; Author: Zhou, et al.; Biochemical Pharmacology; vol. 65, pp. 51-57, 2003.
Tanshinone (Salvia miltiorrhzae Extract) Preparations Attentuate Aminoglycoside-Induced Free Radical Formation In Vitro and Ototoxicity In Vivo; Author; Wang, et al.; Antimicrobial Agent & Chemotherapy; vol. 47, No. 6; pp. 1836-1841, Jun. 2003.
International Search Report ; International Applicaton No. PCT/KR2004/003546; International Filing date: Dec. 30, 2004; Date of Mailing Mar. 11, 2005.
Written Opinion for Application No. PCT/KR2004/003546 dated Dec. 30, 2004.
International Preliminary Exam Report for Application No. PCT/KR2004/003546 dated Dec. 30, 2004.

Affiliated with

Also associated with

Rating

Obesity and metabolic syndrome treatment with tanshinone... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Obesity and metabolic syndrome treatment with tanshinone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Obesity and metabolic syndrome treatment with tanshinone... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4282888